Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch

Publisher： Karger

E-ISSN： 1423-0194|97|1|57-66

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.97, Iss.1, 2012-02, pp. : 57-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

By  

Neuroendocrinology, Vol. 91, Iss. 3, 2010-04 ,pp. : 268-278

Karger

Access to resources Recommend Favorite

Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors

By  

Neuroendocrinology, Vol. 103, Iss. 5, 2015-11 ,pp. : 592-604

Karger

Access to resources Recommend Favorite

EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets

By  

Neuroendocrinology, Vol. 97, Iss. 1, 2012-06 ,pp. : 35-44

Karger

Access to resources Recommend Favorite

Hypothalamic Preproghrelin Gene Expression Is Repressed by Insulin via Both PI3-K/Akt and ERK1/2 MAPK Pathways in Immortalized, Hypothalamic Neurons

By  

Neuroendocrinology, Vol. 89, Iss. 3, 2008-10 ,pp. : 267-275

Karger

Access to resources Recommend Favorite

Interleukin-1β Plays a Pivotal Role via the PI3K/Akt/mTOR Signaling Pathway in the Chronicity of Mesial Temporal Lobe Epilepsy

By  

Neuroimmunomodulation, Vol. 23, Iss. 5-6, 2017-04 ,pp. : 332-344

Karger

Access to resources Recommend Favorite